Data as of Dec 06
| -0.28 / -2.19%|
The 3 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 26.75, with a high estimate of 35.00 and a low estimate of 24.00. The median estimate represents a +114.17% increase from the last price of 12.49.
The current consensus among 2 polled investment analysts is to Buy stock in Cancer Genetics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.